The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models

This publication has 65 references indexed in Scilit:

• Synergistic induction of apoptosis by a polo‐like kinase 1 inhibitor and microtubule‐interfering drugs in Ewing sarcoma cells
  International Journal of Cancer, 2015
• Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma
  Cancer Letters, 2015
• Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children
  Cancer Research, 2013
• In vitro targeting of Polo-like kinase 1 in bladder carcinoma
  Cancer Biology & Therapy, 2013
• MYCN-mediated overexpression of mitotic spindle regulatory genes and loss of p53-p21 function jointly support the survival of tetraploid neuroblastoma cells
  Cancer Letters, 2013
• Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
  Clinical Cancer Research, 2011
• MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma
  BMC Cancer, 2011
• Neuroblastoma: Therapeutic strategies for a clinical enigma
  Cancer Treatment Reviews, 2010
• Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
  Proceedings of the National Academy of Sciences, 2005
• Polo-like kinase-1 is a target of the DNA damage checkpoint
  Nature Cell Biology, 2000